Category Added in a WPeMatico Campaign
CONCLUSION: As reported in Mohs et al. (2024), progression on the primary clinical/cognitive endpoint of the Clincial Dementia Rating Scale Sum of Boxes score (CDR-SB) occurred over the 78-week protocol in the HOPE4MCI study and non-carriers of ApoE4 treated with AGB101 showed a substantially more favorable effect than carriers. Here we report that treatment with…
CONCLUSION: Women seem to be more interested in initiatives promoting healthy aging. We have observed differences in dementia risk factors between men and women that could be related to sociocultural gender differences in this range of age. As previous studies have shown, in our study women perform better on brief cognitive tests, making them less…
CONCLUSION: Our estimation supports the potential cost-effectiveness of multimodal intervention trials, exemplified by J-MINT, for dementia prevention.
CONCLUSION: Four possible multidomain adherence composite scores are proposed, reflecting intervention engagement in U.S. POINTER. In the future, we will explore sensitivity of each composite score to detect treatment-related change in cognition. This study will lay the foundation for broader applications in other multidomain trials with quantifiable adherence metrics, such as FINGER and LatAm-FINGERS.
CONCLUSIONS: The IPAT Study had a success with total recruitment yield from the hospital database sources, but less success with virtual resources, referrals, and community outreach activities. However, a multimodal recruitment approach is essential to meet the overall enrollment goal of the project.
CONCLUSION: PlwD had a broad array of unmet healthcare needs, indicating primary healthcare provision improvement potentials. The results underscore the significance of early assessment of patient’s clinical characteristics and unmet needs as a basis for individualized gender-sensible intervention strategies.
CONCLUSION: Benfotiamine reverses the changes of metabolites/lipids reflecting AD progression. Our ongoing NIH funded multicenter trial includes blood biomarkers of thiamine, amyloid, tau, inflammation, neurodegeneration, AGE, and extensive cognitive testing. A larger sample size is necessary to test whether metabolic biomarkers are useful for disease diagnosis, prognosis, and monitoring therapeutic efficacy. This research was partially…
CONCLUSION: Preliminary findings from LatAm-FINGERS highlight the feasibility of conducting intervention trials within diverse populations. These findings underscore the importance of creating recruitment strategies that effectively engage underrepresented groups. This contributes significantly to global Alzheimer’s disease research efforts. The trial’s experience offers a valuable model for inclusive enrollment practices in Alzheimer’s disease and related dementia…
CONCLUSION: AXS-05 demonstrated a substantial, rapid reduction in ADA vs controls after 5 weeks of treatment, increased time-to-relapse vs placebo, and was well-tolerated, supporting its development as a promising treatment option for ADA.
CONCLUSION: A single bout of tVNS does not appear effective for improving cognition in individuals with MCI.